Literature DB >> 1611524

Effects of nicotine on spatial memory deficits in rats with septal lesions.

M W Decker1, M J Majchrzak, D J Anderson.   

Abstract

Impaired septohippocampal function has been implicated in the memory deficits associated with Alzheimer's disease (AD), and septal lesions have been used to model the cognitive deficits associated with AD. In this study, we assessed the effects of systemic administration of nicotine on lesion-induced deficits in the acquisition of a spatial discrimination version of the Morris water maze. Rats with radiofrequency lesions of the medial septum were required to learn which of two visible platforms in a pool of water provided a means of escape. On each of the first 4 days of training, the rats received an injection of (-)nicotine (0, 0.1 or 0.3 mg/kg, i.p.) before training. Nicotine markedly improved the performance of septal rats. This enhanced performance was maintained in rats subsequently tested 1 and 15 days later without additional drug treatment. Septal rats initially trained under nicotine were impaired, however, when the platform locations were reversed and training was conducted under saline. Our findings suggest that nicotinic receptor stimulation might be useful in the treatment of cognitive deficits.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1611524     DOI: 10.1016/0006-8993(92)90485-r

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  21 in total

1.  Low-dose nicotine facilitates spatial memory in ApoE-knockout mice in the radial arm maze.

Authors:  Ruby Sultana; Kiyoshi Ameno; Mostofa Jamal; Takanori Miki; Naoko Tanaka; Junichiro Ono; Hiroshi Kinoshita; Yu Nakamura
Journal:  Neurol Sci       Date:  2012-07-07       Impact factor: 3.307

2.  Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice.

Authors:  R Paylor; M Nguyen; J N Crawley; J Patrick; A Beaudet; A Orr-Urtreger
Journal:  Learn Mem       Date:  1998 Sep-Oct       Impact factor: 2.460

Review 3.  Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

Authors:  P A Newhouse; A Potter; E D Levin
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

4.  Cannabinoid receptor CB1 is involved in nicotine-induced protection against Aβ1-42 neurotoxicity in HT22 cells.

Authors:  Mingchun Wu; Ji Jia; Chong Lei; Ling Ji; Xiaodan Chen; Hanfei Sang; Lize Xiong
Journal:  J Mol Neurosci       Date:  2014-09-28       Impact factor: 3.444

Review 5.  Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression.

Authors:  Jason A Gandelman; Paul Newhouse; Warren D Taylor
Journal:  Neurosci Biobehav Rev       Date:  2017-08-30       Impact factor: 8.989

6.  Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement.

Authors:  J J Buccafusco; W J Jackson; A V Terry; K C Marsh; M W Decker; S P Arneric
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

7.  Nicotinic and muscarinic agonists and acetylcholinesterase inhibitors stimulate a common pathway to enhance GluN2B-NMDAR responses.

Authors:  Masaru Ishibashi; Yoshihiko Yamazaki; Ricardo Miledi; Katumi Sumikawa
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

8.  Acute and chronic nicotine effects on working memory in aged rats.

Authors:  E D Levin; D Torry
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

9.  Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats.

Authors:  J Turchi; L A Holley; M Sarter
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

10.  Effects of nicotine and mecamylamine on cognition in rhesus monkeys.

Authors:  Simon N Katner; Sophia A Davis; Amber J Kirsten; Michael A Taffe
Journal:  Psychopharmacology (Berl)       Date:  2004-04-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.